Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome

Inclusion Criteria: * Male or female patients aged between 18 and 80 years. * Patients with diagnosis of Dumping Syndrome: * Having symptoms of Dumping Syndrome (sum of combined Dumping Syndrome score ≥10) AND * either (a) having had a documented episode of postprandial hypoglycemia in the medical history * or either (b) demonstrating a hypoglycemia (\<60mg/dl) or hematocrite increase of \> 3% or a pulse increase of 10 bpm after an oral glucose tolerance test with 75 g of glucose. * Patients for whom written informed consent to participate in the study has been obtained. Patients will need to provide their informed consent prior to starting any medication washout period Exclusion Criteria: * Patients who have undergone major surgery/surgical therapy for any cause within 1 month * Patients with symptomatic cholecystolithiasis in the medical history unless a cholecystectomy is performed (ultrasound abdomen maximum 6 months old). * Patients who have failed treatment with somatostatin analogues in the past (specifically patients who have been treated with octreotide s.c. for more than 2 days or with a long acting somatostatin analogue for more than 8 weeks). * Patients who have been treated with somatostatin analogues during the last 12 weeks before inclusion. * Patients who have a known hypersensitivity to somatostatin analogues. * Patients with the diagnosis of Diabetes Mellitus * Patients with important co-morbidity (cardiac, pulmonary, renal , hepatic diseases) * Pati…